These are the four lines found on the bottom of the front page of POET's website.
Any company claiming even just one of the four would be considered a serious investment by any investor. And yet, POET claims all four and the market in general is full of naysayers. Perhaps, it's precisely that, that POET is claimning not one, two, but all four. Pretty outrageous!
It's been truly frustrating being a shareholder. So much seem to be shrouded behind NDAs and the path taken to commercialization seem puzzling at the best of times. And yet, here we are at the cusp of a very important moment in the POET story, the annoucement of the first product prototype.
Are we to expect the atypical that we have come to expect of PTK? NREs, product development, customer testing, licensing, etc etc, the typical path to commercialization.
Well, I'm betting that soon the very opposite will occur. If even one of the four claims are proven true, there's no way that this company will not have a significant stakeholder and or a complete buyout. When we least expect the unexpected, expect the unexpected. GLTA
- First gallium arsenide semiconductor technology to support integration of high speed electronics and high speed photonics
- POET enables a Moore’s Law like functional integration to the field of optics
- Compatible with existing manufacturing technology and computing ecosystem
- Versatile technology platform with a DIVERSE set of applications
